Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Tubulointerstitial nephritis (TIN) presents as an acute or subacute renal impairment and has a wide range of causes, including medications, autoimmune diseases, and idiopathic factors. Statins are widely prescribed and are generally well tolerated; however, nephrotoxicity has occasionally been reported. Herein, we report a rare case of TIN caused by rosuvastatin, complicated by Fanconi syndrome. In this case, prompt diagnosis and early therapeutic intervention resulted in a favorable outcome.
A 64-year-old woman had been receiving treatment for hypertension and dyslipidemia since her 50s, without any resulting abnormalities in kidney function. Three months before her visit, she developed loss of appetite following an upper respiratory tract infection, and subsequent tests revealed renal dysfunction (serum creatinine 1.52 mg/dL). Her creatinine level continued to rise to 2.87 mg/dL, and she was referred to our hospital for further evaluation. Upon admission, laboratory tests revealed hypokalemia, hypouricemia, glycosuria, and metabolic acidosis with a normal anion gap, suggesting a complication of Fanconi syndrome. Immunological testing revealed the absence of antinuclear antibodies, anti-SS-A antibodies, antineutrophil cytoplasmic antibodies, and monoclonal proteins. Serum angiotensin-converting enzyme and immunoglobulin G4 levels were within normal ranges, and no lesions were evident in other organs. A kidney biopsy showed no significant abnormalities in the glomeruli. However, there was widespread infiltration of inflammatory cells and tubulitis in the tubulointerstitial area, leading to the diagnosis of tubulointerstitial nephritis.
Oral prednisolone (40 mg/day) was initiated, which resulted in a marked improvement in renal function. To identify the causative drug, a drug-induced lymphocyte stimulation test was performed, which revealed a positive reaction to rosuvastatin. The drug was discontinued and replaced with ezetimibe for lipid management purposes. Even after tapering and discontinuation of the corticosteroids, there was no recurrence of renal dysfunction or resurgence of Fanconi symptoms, and renal function remained stable with a favorable course.
This is a rare case of drug-induced tubulointerstitial nephritis complicated by Fanconi syndrome, which was suspected to be associated with rosuvastatin use. Although there have been a few reports on statin-related interstitial nephritis, the concurrence of Fanconi syndrome has not been documented. The favorable outcomes following drug discontinuation, corticosteroid therapy, and a safe switch to ezetimibe highlight the importance of early diagnosis and appropriate management of this condition.
